Inhibikase Therapeutics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Clinical-stage pharmaceutical company developing protein kinase inhibitors for Parkinson’s disease, Parkinson’s-related disorders, including multiple system atrophy (MSA), and other Abelson Tyrosine Kinase-related diseases. The company also develops IkT-001Pro, a prodrug of imatinib for stable-phase chronic myelogenous leukemia. This unaudited report covers the three months ended March 31, 2023.
- The FDA lifted the clinical hold on the Parkinson’s programs in January 2023 and on the MSA program in March 2023.
- The Phase 2a Parkinson’s 201 trial had 20 of 36 planned sites opened and 7 sites screening patients as of the filing date.
- Four of four IkT-001Pro dose-escalation cohorts were complete; management expected the dose-finding and dose-equivalence program to conclude by the end of the second quarter of 2023.
Financial Performance and Liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Grant revenue | $64,521 | $46,031 | Up 40.2% |
| Research and development expense | $2.85 million | $3.02 million | Down 5.4% |
| SG&A expense | $1.93 million | $1.67 million | Up 15.3% |
| Loss from operations | $(4.71) million | $(4.64) million | Loss increased $74,353 |
| Net loss | $(4.48) million | $(4.64) million | Loss decreased $162,823 |
| Net loss per share | $(0.16) | $(0.18) | Improved |
| Cash used in operating activities | $(5.97) million | $(3.93) million | Use increased $2.04 million |
- Interest income was $237,171, compared with essentially zero in the prior-year period, primarily from U.S. Treasury securities and money-market instruments.
- March 31, 2023 cash and cash equivalents were $3.96 million, and marketable securities were $21.76 million, consisting of U.S. Treasury obligations. Total cash and marketable securities were approximately $25.7 million.
- Working capital was $24.96 million; current liabilities were $2.66 million. The company reported no material debt other than operating lease obligations totaling $325,011.
- Accumulated deficit was $52.35 million. The company has no product-sales revenue and remains dependent on grants and external financing.
- Management estimated that existing working capital would fund normal operations into the fourth quarter of 2024, although the estimate depends on assumptions that may prove incorrect.
Material Changes Versus the Prior Comparable Period
- R&D expense declined $162,872, primarily reflecting changes in program spending as the Phase 2a trial resumed following release of the clinical hold.
- PD-related R&D declined by approximately $761,000 and MSA-related R&D declined by approximately $115,000, while CML-related R&D increased by approximately $692,000.
- SG&A increased $255,715, driven principally by higher legal and consulting fees, promotional costs, and other administrative expenses.
- Operating cash burn increased substantially, partly due to changes in prepaid expenses, accounts payable, and accrued liabilities.
- The January 2023 financing generated approximately $8.6 million of net proceeds and increased common shares outstanding to 31,056,238 at March 31, 2023 from 25,227,051 at December 31, 2022. The financing also included substantial common and pre-funded warrants, creating potential future dilution.
- The company invested cash in marketable securities during the quarter. The cash-flow statement reports purchases of $21.61 million and maturities of $15.77 million; the MD&A discussion presents different amounts, which should be reconciled.
Guidance, Outlook, Risks, and Unusual Items
- Management expects continued significant losses and increasing development costs as clinical programs advance. Additional capital is expected to be required through equity, debt, grants, licensing, or collaboration arrangements.
- The 201 Parkinson’s trial is planned to evaluate 50 mg and 100 mg doses, with the 200 mg dose reintroduced on a staggered basis. Additional ocular monitoring was requested for the 200 mg dose.
- The company plans to pursue a potential Phase 2 MSA study, subject to supportive animal-model results, and intends to discuss the IkT-001Pro NDA pathway with the FDA under Section 505(b)(2).
- Nasdaq notified the company that it did not meet the $1.00 minimum closing bid-price requirement. The company had until July 24, 2023 to regain compliance and indicated that a reverse stock split could be used. As of May 15, 2023, compliance had not been regained, creating a potential delisting risk.
- Key risks include further clinical holds, trial delays or failures, adverse safety findings, regulatory rejection, inability to raise capital, dilution, dependence on third-party manufacturers and research organizations, intellectual-property challenges, market volatility, and the absence of commercial product revenue.
- The filing states that there was no material litigation, no off-balance-sheet arrangements, and no material change in internal control over financial reporting.
Important Facts for Investors to Verify
- Reconcile the inconsistent marketable-securities purchase and maturity amounts reported in the cash-flow statement and MD&A.
- Monitor cash burn, remaining grant availability, and the timing and terms of future financing.
- Track enrollment, safety, ocular monitoring, and regulatory status of the Phase 2a Parkinson’s trial.
- Confirm completion and FDA follow-up for the IkT-001Pro 501 trial and the proposed 505(b)(2) pathway.
- Verify whether the company regained Nasdaq’s minimum bid-price compliance or pursued a reverse stock split before the July 24, 2023 deadline.
- Assess potential dilution from approximately 24.2 million shares underlying outstanding options and warrants at March 31, 2023.